DiaSorin SpA (MILAN:DIAS) projected revenue growth of 5% to 6% for 2026.
The company also forecast a compound annual growth rate of 6% to 8% from 2026 through 2030.
Adjusted EBITDA margin is expected at 32% to 33% for 2026, expanding to 34% to 35% by 2030.
DiaSorin anticipates cumulative free cash flow of approximately €1 billion between 2027 and 2030.
Shares of DiaSorin fell about 1% in Milan on Wednesday following the announcement.












